Cargando…

Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19

In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodro, Marta, Cofan, Frederic, Ríos, Jose, Herrera, Sabina, Linares, Laura, Marcos, María Angeles, Soriano, Alex, Moreno, Asunción, Diekmann, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067800/
https://www.ncbi.nlm.nih.gov/pubmed/33917093
http://dx.doi.org/10.3390/jcm10081551
_version_ 1783682887449575424
author Bodro, Marta
Cofan, Frederic
Ríos, Jose
Herrera, Sabina
Linares, Laura
Marcos, María Angeles
Soriano, Alex
Moreno, Asunción
Diekmann, Fritz
author_facet Bodro, Marta
Cofan, Frederic
Ríos, Jose
Herrera, Sabina
Linares, Laura
Marcos, María Angeles
Soriano, Alex
Moreno, Asunción
Diekmann, Fritz
author_sort Bodro, Marta
collection PubMed
description In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.
format Online
Article
Text
id pubmed-8067800
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80678002021-04-25 Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 Bodro, Marta Cofan, Frederic Ríos, Jose Herrera, Sabina Linares, Laura Marcos, María Angeles Soriano, Alex Moreno, Asunción Diekmann, Fritz J Clin Med Article In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed. MDPI 2021-04-07 /pmc/articles/PMC8067800/ /pubmed/33917093 http://dx.doi.org/10.3390/jcm10081551 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bodro, Marta
Cofan, Frederic
Ríos, Jose
Herrera, Sabina
Linares, Laura
Marcos, María Angeles
Soriano, Alex
Moreno, Asunción
Diekmann, Fritz
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_full Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_fullStr Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_full_unstemmed Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_short Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_sort use of anti-cytokine therapy in kidney transplant recipients with covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067800/
https://www.ncbi.nlm.nih.gov/pubmed/33917093
http://dx.doi.org/10.3390/jcm10081551
work_keys_str_mv AT bodromarta useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT cofanfrederic useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT riosjose useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT herrerasabina useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT linareslaura useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT marcosmariaangeles useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT sorianoalex useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT morenoasuncion useofanticytokinetherapyinkidneytransplantrecipientswithcovid19
AT diekmannfritz useofanticytokinetherapyinkidneytransplantrecipientswithcovid19